GTBP vs HCWB

GT Biopharma, Inc. vs HCW Biologics Inc. — Valuation Comparison 2026

GTBP

Biotechnology
GT Biopharma, Inc.
Quality
3.5
out of 10
Value Trap
24
SAFE
Price
$0.45
Last close
Models
8/13
Active
VS

HCWB

Biotechnology
HCW Biologics Inc.
Quality
3.9
out of 10
Value Trap
38
LOW
Price
$2.09
Last close
Models
6/13
Active

Model-by-Model Comparison

ModelType GTBP Fair ValueGTBP Upside HCWB Fair ValueHCWB Upside
Bayesian DCF Intrinsic $0.25 -42.8%
Earnings Power Value Intrinsic $0.29 -35.1%
First Chicago Scenario $•••.•• ••.•% $•••.•• ••.•%
Markov DDM Intrinsic $0.06 -83.6%
ML-RIV Intrinsic $•••.•• ••.•% $•••.•• ••.•%
Dynamic NAV Asset-Based $1.74 +289.9% $0.35 -83.3%
PWERM Option-Based $•••.•• ••.•% $•••.•• ••.•%
Regime Cross-Sectional Relative $•••.•• ••.•% $•••.•• ••.•%
Sentiment SOTP Hybrid $•••.•• ••.•% $•••.•• ••.•%
CUCE Ensemble Ensemble $•••.•• ••.•% $•••.•• ••.•%
🔒

Unlock Full 13-Model Comparison

Access all valuation models for GTBP vs HCWB — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

GTBP vs HCWB — Which Stock Is More Undervalued?

HCWB scores higher with a 3.9/10 quality rating vs GTBP's 3.5/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing GT Biopharma, Inc. (GTBP) and HCW Biologics Inc. (HCWB) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

GTBP currently trades at $0.45 with a QOC of 3.5/10, while HCWB trades at $2.09 with a QOC of 3.9/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).